COSTLY EOULIZUMAB GETS GREEN LIGHT FROM NICE

摘要

Eoulizumab, dubbed "the world's most expensive drug", and described as "a step change in the management of atypical haemolytic uraemio syndrome (aHUS)", is being made available on the NHS in England. But the National Institute for Health and Care Excellence (NICE) has attached conditions to the use of eoulizumab (Soliris), which costs ￡340,200 per patient per year, according to guidance produced as part of NICE'S highly specialised technologies programme.